Hello and welcome back.

Thank you to everyone who registered for our Mental Health Town Hall. We can’t wait to connect with you! If you haven’t signed up yet, don’t worry, it’s not too late. Keep reading for details.

Here’s what’s in store for you in today’s issue:

🍄 How psychedelics helped an ancient empire maintain power

🍄 Add some ecstasy to your sex life

🍄 Microdosing DMT

🍄 Australian gov’t funds 2 psychedelic studies

🍄 And more.

Be sure to check out this week’s Daily Mushroom podcast:

Healing at home with Nue Life’s innovative ketamine wellness program

In this episode of the Daily Mushroom Podcast, we have Juan Pablo Cappello, co-founder and CEO of Nue Life Health. Nue Life’s at-home ketamine wellness program is proving to be highly beneficial for patients with treatment-resistant depression. The key is in the company’s unique approach to integration, which utilizes intuitive AI, music therapy, and group support

Nue Life is a public benefits corporation, and its entire founding team is made up of people of colour and women. Learn how Juan Pablo Cappello used spiritual wisdom to create a conscious business in his talk, 4 Pillars of Conscious Startups.

This will be an inspiring event for anyone who dreams of running a tech startup or wants to bring conscious leadership to their workplace.

Therapeutic banner

Add some ecstasy to your sex life

Over 90% of people experienced increased sexual desire and satisfaction after taking MDMA. But that’s not the only way it can improve your sex life.

Mindcure (MCUR) is studying MDMA-assisted-therapy as a treatment for Hypoactive Sexual Desire Disorder (HSDD), which is characterized by low sex drive and emotional distress. 

The goal is to use MDMA to get to the root cause of the issue, which may be a history of negative sexual experiences and relationships or struggles with self worth or body image.

Microdosing DMT

Algernon Pharmaceuticals (AGN) found that microdoses of DMT can increase the growth of neurons in the brain by up to 40%. An upcoming study will see if this can benefit stroke patients.

Phase I of the study, which is awaiting approval in the UK, will determine the maximum amount of DMT that can be taken without producing a psychedelic effect. Phase II will test repeated doses on acute and recovering stroke patients.

Treating alcoholism in Europe

Last year, Awakn Life Sciences (AWKN) found that MDMA-assisted therapy helped alcoholics reduce alcohol consumption by 85% – from an average of 130.6 units per week to just 18.7.

Now, the company is exploring a partnership with the Multidisciplinary Association for Psychedelic Studies (MAPS) to treat alcohol use disorder across Europe, where alcohol is one of the top five causes of disease and disability in most countries. Awakn may license MAPS’ pre-clinical data to get the treatment to market faster.

Microdosing eases depression

In a preclinical animal model, Wesana Health (WESA) found that a single high dose of psilocybin rapidly improved depressive behaviours for 14 days. A regimen of psilocybin microdoses and CBD was able to sustain the results and reduced depressive behaviours by an additional 64%.

Let’s keep the microdosing evidence coming!

inspirational banner

Be an industry insider

How can DMT be improved to better treat addiction? How do our genetics influence our psychedelic experiences? How does ketamine change our brain wave patterns? Does music make psychedelic therapy more effective?

These are all questions that Entheon Biomedical (ENBI) is answering with ongoing clinical research. Learn what they’ve discovered so far and their next steps at our Mental Health Town Hall this February 3rd!

We’ll be joined by Entheon’s Founder and CEO, Scientific Advisor, and Communications Manager to discuss the company’s findings and the future of psychedelic therapy. Register now for free to get the inside scoop 👇

Save the toads

Did you know that potent psychedelics like 5-MeO-DMT and bufotenin come from the venom of the Colorado River Toad? 

With growing demand to study these compounds and increased recreational use, wild populations of the toad are threatened in some areas.

Alvarius Research Inc. recently developed a toad conservation program to address this issue. The company is also collaborating with Egret Bioscience to develop synthetic “toad-free” versions of the compounds.

Psychedelics → power?

An ancient South American empire called the Wari Empire may have used a hallucinogenic beer to maintain its power.

The Wari people brewed a beer-like drink with seeds from the vilca tree, which contain a psychedelic compound called bufotenin (one of the substances found in toad venom!). 

Archeologists believe that Wari leaders served the drink at feasts to strengthen social connections with guests from surrounding regions. Guests likely had a euphoric or spiritual experience, compelling them to “acknowledge the power of their hosts or feel the need to owe them a favor in the future,” explains one archeology expert. 

Could this be why the empire maintained political control for hundreds of years? 🤔

Connect with your microdosing community

If you’re looking to try microdosing, what better way to get started than with a community of like-minded individuals. 

Dose Day is a microdosing peer support network that connects you with a small group with similar intentions and interests. Meet with your group weekly to see how the power of community can support you on your journey.

Whether you’re an artist, an executive, a consciousness junkie or someone looking to improve their mental health, there is a group for you.

Plus, half the fee supports palliative care patients with end-of-life anxiety.

business banner

Psygen Industries Ltd. is building Canada’s first manufacturing facility dedicated to synthetic psychedelics. The company received authorization to produce and sell psilocybin, psilocin, LSD, DMT, mescaline, and 2C-B through a Health Canada Dealer’s License. It has already established over 20 supply agreements with domestic and international companies 👏

Numinus Wellness (NUMI) is enrolling patients for a multi-site study on MDMA for PTSD, which will be sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS). The study received approval from both Health Canada and the Institutional Ethics Review Board.

Eleusis, a UK-based company focused on psilocybin therapy for depression, is planning to go public through a $446M merger with Silver Spike Acquisition Corp. II (SPKB). Eleusis will apply to have its shares listed on the NASDAQ under the symbol ‘ELEU’.

Red Light Holland (TRIP) is collaborating with an advocacy group called the Psychedelic Medicine Alliance Washington to promote a bill that would legalize guided psilocybin sessions in Washington State. The company has hired a lobbyist with experience in cannabis regulation and is launching a social media campaign and educational events to raise awareness about the benefits of psilocybin.

legal banner

Here’s what you missed in the legal world:

  • University of Sydney researchers received $3M in funding from the Australian government to support MDMA and psilocybin studies! The MDMA study will investigate combined PTSD and alcohol use disorder, and the psilocybin study will be focused on anorexia nervosa. Read more…
  • A Kansas legislator filed a bill to legalize the possession of up to 50 grams of psilocybin or psilocin, as well as the cultivation of psilocybin mushrooms. Read more…
  • A Utah Rep. filed a bill that would establish a task force to research the therapeutic potential of psychedelics. Read more…
  • Representatives from seven US states (Oregon, Nebraska, Michigan, Arizona, Texas, Minnesota, and Pennsylvania) have submitted a letter urging the Drug Enforcement Administration (DEA) to allow terminally-ill patients access to psilocybin treatments. The lawmakers believe that psilocybin qualifies as an investigational drug and should therefore be accessible through Right to Try laws. Read more…

Video of the Week

Playlist of the Week